Lessons of leprosy: The emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 626-630

  Martiniuk, Frank ^a   Giovinazzo, Jerome ^a   Tan, Ainah U ^a   Shahidullah, Rozana ^b   Haslett, Patrick ^c   Kaplan, Gilla ^d   Levis, William R ^a  

^a NEW YORK UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c SHIRE   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD70 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 17; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 25; PARAFFIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; ERYTHEMA NODOSUM LEPROSUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MALE; NEPAL; PLASTICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SKIN BIOPSY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; UPREGULATION;

ADOLESCENT; ADULT; BIOPSY; CYTOKINES; ERYTHEMA NODOSUM; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TH17 CELLS; THALIDOMIDE; UP-REGULATION; YOUNG ADULT;

EID: 84860892443     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Burnet FM. The new approach to immunology. N Engl J Med. 1961;5:264:24-34.
2. Miller JF. Immunological function of the thymus. Lancet. 1961;2:748-749.
3. Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119-128.
4. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255-273.
5. Nogueira N, Kaplan G, Levy E, et al. Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med. 1983;158:2165-2170. (Pubitemid 14210812)
6. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277-279. (Pubitemid 21917340)
7. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348-2357. (Pubitemid 16136806)
8. Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009;9:811-816.
9. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
10. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139-145.
11. Voo KS, Wang YH, Santori FR, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci. 2009;106:4793-4798.
12. Massone C, Nunzi E, Ribeiro-Rodrigues R, et al. T regulatory cells and plasmocytoid dentritic cells in hansen disease: a new insight into pathogenesis? Am J Dermatopathol. 2010;32:251-256.
13. Attia EA, Abdallah M, Saad AA, et al. Circulating CD4+ CD25 high FoxP3+ T cells vary in different clinical forms of leprosy. Int J Dermatol. 2010;49:1152-1158.
14. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
15. Haslett PA, Roche P, Butlin CR, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis. 2005;192:2045-2053. (Pubitemid 41779200)
16. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892. (Pubitemid 28262451)
17. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 1995;31:109-116.
18. Stockinger B, Hirota K, Duarte J, Veldhoen M. External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin Immunol. 2011;23:99-105.
19. Nguyen NT, Kimura A, Nakahama T, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine- dependent mechanism. Proc Natl Acad Sci. 2010;107:19961-19966.
20. Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185:3190-3198.
21. de Souza Sales J, Lara FA, Amadeu TP, et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol. 2011;165:251-263.
22. Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity. 2009;31:974-985.
23. Park E, Levis WR, Greig N, et al. Effect of thalidomide on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells. J Drugs Dermatol. 2010;9:330-333.
24. Niedbala W, Alves-Filho JC, Fukada SY, et al. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. Proc Natl Acad Sci. 2011;108:9220-9225.
25. Lockwood DN, Suneetha L, Sagili KD, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the north Indian INFIR cohort. PLoS Negl Trop Dis. 2011;5:e1327.
26. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011;140:957-965.
27. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002;8:1964-1973. (Pubitemid 34633760)
28. Ando Y, Price DK, Dahut WL, et al. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002;1:669-673.
29. Ramirez JM, Brembilla NC, Sorg O, et al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol. 2010;40:2450-2459.
30. Jabbari A, Johnson-Huang LM, Krueger JG. Role of the immune system and immunological circuits in psoriasis. G Ital Dermatol Venereol. 2011;146:17-30.